<<
>>

Pyrazinamide

TREATMENT

Pyrazinamide (15-30 mg/kg PO q24h [maximum, 2 g] or 50-75 mg/kg PO twice a week [maximum, 4 g/dose]) kills mycobacteria by an unknown disruption of membrane transport. It is well absorbed orally and widely distributed throughout the body, including the CSF. Pyrazinamide is typically used for the first 2 months of therapy during treatment of active TB.

SPECIAL CONSIDERATIONS

Adverse events include hyperuricemia and hepatitis.

<< | >>
Source: Ancha S., Auberle C., Cash D., Harsh M., Hickman J., Kounga C.. The Washington Manual of Medical Therapeutics, 37th edition, LWW, 2022. —1250p.. 1250
More medical literature on Medic.Studio

More on the topic Pyrazinamide:

  1. Pyrazinamide
  2. Sideroblastic Anemias
  3. Tuberculosis Caused by M. bovis in Humans in Uganda
  4. Nontuberculous Mycobacteria
  5. Bacterial infections
  6. Monoclonal Gammopathy of Unknown Significance
  7. Drug Susceptibility Testing Definition and Description
  8. Disruption
  9. Macrovascular Complications of Diabetes Mellitus